European Association of Urology

GE HealthCare closes MIM Software acquisition, bolstering its portfolio and advancing its precision care strategy

Retrieved on: 
Monday, April 1, 2024
Technology, Health, Other Health, Radiology, Oncology, Other Technology, Practice Management, Medical Devices, Software, Managed Care, General Health, Health Technology, Hardware, Data Management, Neurology, Automation, Diagnosis, Cardiology, Molecular imaging, American Urological Association, MRI, Prostate cancer, Nuclear medicine, SNMMI, Patient, PET, Radiation, Cancer, Society, Adjustment, Radiation therapy, Workflow, Radiopharmaceutical, GE HealthCare, SPECT, MIM, Brachytherapy, ASCO, European Association of Urology, Hand, Medical imaging

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.

Key Points: 
  • The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.
  • "We are thrilled to welcome MIM Software, known for driving innovation in multimodal image analytics and workflow, to our global GE HealthCare team,” said Peter Arduini, President & CEO, GE HealthCare.
  • “These new capabilities align with our precision care strategy to personalize care, enhance hospital efficiency and clinician effectiveness, and appeal to new and existing GE HealthCare and MIM Software users who see this as an opportunity to better serve patients and help improve outcomes."
  • “Today marks an exciting new chapter for our team and technology,” adds Andy Nelson, CEO, MIM Software at GE HealthCare.

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Retrieved on: 
Wednesday, March 13, 2024
Taboo, Anxiety, Woman, Mental health, Ticker, Doctor of Philosophy, EAU, Neurostimulation, Urethra, MD, Pathology, Nursing, Quality of life, Female, Prostate, Urinary incontinence, Hope, Life, European, Health, Incontinence, Medtech, Patient, Disorder, Child, Male, European Association of Urology, Trial of the century, Ageing, Animation, Wound healing, Medical device

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Key Points: 
  • Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.
  • This first implantation of the artificial urinary sphincter Artus was successfully performed by Prof. Roman Zachoval, MD, PhD, head of the Department of Urology at Thomayer University Hospital in Prague, Czech Republic, on a 68-year-old male with severe urinary incontinence.
  • “Artus is easy to prepare and implant due to its innovative design compared to the previous generation of urinary sphincters.
  • Artus is an implantable artificial urinary sphincter developed for the treatment of moderate to severe urinary incontinence in both men and women.

EQS-News: invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma

Retrieved on: 
Friday, December 15, 2023
Immune system, Survival, MD, Brain, Harvard Medical School, Neuro-Oncology (journal), Science, Cancer, Research, Cytokine, European Association of Urology, Doctor of Philosophy, Temozolomide, Radiation, Gesellschaft mit beschränkter Haftung, Dana–Farber Cancer Institute, Patient, Traffic barrier, Glioblastoma, Biotechnology, Pharmaceutical industry, Medical imaging, Medicine, Boston

Preclinical study will be conducted by Dr. David Reardon’s research group

Key Points: 
  • Preclinical study will be conducted by Dr. David Reardon’s research group
    Vienna, Austria and Boston, MA USA, 9 November 2023: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate invIOs’ small molecule INV501 as a potential treatment for glioblastoma.
  • The collaboration will be led by David Reardon, MD, Clinical Director, Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
  • Dr. Reardon is a world-renowned expert in brain cancer, particularly glioblastoma research and treatment.
  • Among these, some compounds can cross the blood-brain barrier and enter the glioblastoma micro-environment to initiate anti-tumoral immune reactions.

invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma

Retrieved on: 
Thursday, November 9, 2023
Survival, Temozolomide, Harvard Medical School, Dana–Farber Cancer Institute, Gesellschaft mit beschränkter Haftung, Biotechnology, MD, Cytokine, Doctor of Philosophy, Research, Traffic barrier, Science, Immune system, Cancer, Radiation, European Association of Urology, Brain, Neuro-Oncology (journal), Patient, Glioblastoma, Pharmaceutical industry, Medical imaging, Medicine

Preclinical study will be conducted by Dr. David Reardon’s research group

Key Points: 
  • Preclinical study will be conducted by Dr. David Reardon’s research group
    VIENNA, Austria and BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate invIOs’ small molecule INV501 as a potential treatment for glioblastoma.
  • The collaboration will be led by David Reardon, MD, Clinical Director, Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
  • Dr. Reardon is a world-renowned expert in brain cancer, particularly glioblastoma research and treatment.
  • After seeing the initial promising preclinical data on INV501 in solid tumors presented by invIOs, we are excited to test this small molecule that crosses the blood-brain barrier in glioblastoma models.

Blue Earth Therapeutics Announces Promising Results of Preclinical Evaluation of 225Ac-rhPSMA-10.1 for Potential Targeted Alpha Therapy of Prostate Cancer

Retrieved on: 
Monday, September 11, 2023
Research, Clinical Trials, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Radioactive decay, PSMA, PET, Nuclear medicine, Trial of the century, Annual general meeting, Oral, European Association of Urology, Therapy, IND, Prostate cancer, Medical imaging

Results showed that both 225Ac-rhPSMA-10.1 and 177Lu-rhPSMA-10.1 demonstrated excellent PSMA binding affinity, high cellular internalization and similar lipophilicity.

Key Points: 
  • Results showed that both 225Ac-rhPSMA-10.1 and 177Lu-rhPSMA-10.1 demonstrated excellent PSMA binding affinity, high cellular internalization and similar lipophilicity.
  • Therapeutic response and efficacy were evaluated in a preclinical prostate cancer model which showed that 225Ac-rhPSMA-10.1 significantly suppressed tumor growth relative to control.
  • 225Ac-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, and the lead alpha-emitting candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals.
  • IND-enabling studies have been completed and we plan to initiate a Phase 1 clinical study of 225Ac-rhPSMA-10.1 in the first half of 2024.”

Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer

Retrieved on: 
Thursday, September 7, 2023
Carcinoma, Maintenance, EANM, PET, Cell, Immunotherapy, Doctor of Philosophy, SCLC, Neoplasm, Patient, Cancer, IB, Diagnosis, SST2, European Association of Urology, Therapy, Recurrence, Safety, Disease, Pharmaceutical industry, Vaccine, Medical imaging

The main objective of the study is to establish a recommended Phase 2 dose and schedule.

Key Points: 
  • The main objective of the study is to establish a recommended Phase 2 dose and schedule.
  • Both the diagnostic agent and therapeutic drug contain Ariceum's proprietary peptide satoreotide, a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SST2), a cell surface protein often overexpressed in certain cancers including small cell lung cancer (SCLC).
  • Further details on the study can be found on Australian Clinical Trials , under identifier Ariceum SSO11O-01.
  • We believe that our lead targeted systemic radiopharmaceutical product satoreotide has the potential to demonstrate positive results in patients with extensive stage small cell lung cancer.

Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer

Retrieved on: 
Thursday, September 7, 2023
Carcinoma, Maintenance, EANM, PET, Cell, Immunotherapy, Doctor of Philosophy, SCLC, Neoplasm, Patient, Cancer, IB, Diagnosis, SST2, European Association of Urology, Therapy, Recurrence, Safety, Disease, Pharmaceutical industry, Vaccine, Medical imaging

The main objective of the study is to establish a recommended Phase 2 dose and schedule.

Key Points: 
  • The main objective of the study is to establish a recommended Phase 2 dose and schedule.
  • Both the diagnostic agent and therapeutic drug contain Ariceum's proprietary peptide satoreotide, a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SST2), a cell surface protein often overexpressed in certain cancers including small cell lung cancer (SCLC).
  • Further details on the study can be found on Australian Clinical Trials , under identifier Ariceum SSO11O-01.
  • We believe that our lead targeted systemic radiopharmaceutical product satoreotide has the potential to demonstrate positive results in patients with extensive stage small cell lung cancer.

Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting

Retrieved on: 
Tuesday, September 5, 2023
Abstract (summary), GBM, Neuro-Oncology (journal), Sun, Glioblastoma, Harvard Medical School, Professor, Patient, UCSF, SAN, Annual general meeting, Poster, European Association of Urology, Sun Yat-sen University Cancer Center, Therapy, UCSF Medical Center, Pharmaceutical industry, Radiation therapy

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that it will be presenting a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting, taking place in Rotterdam, September 21-24, 2023.

Key Points: 
  • SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that it will be presenting a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting, taking place in Rotterdam, September 21-24, 2023.
  • The presentation will include data from its lead program, VAL-083, for the treatment of recurrent glioblastoma.
  • Kintara recently hosted an event featuring key opinion leaders Patrick Y. Wen, M.D.
  • (UCSF Health) discussing the current treatment landscape for patients suffering from GBM along with Kintara's potential treatment solution with VAL-083.

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
HIV Vaccine Trials Network, GSK, Corporate Affairs, EASL, Sotrovimab, HIV, Investment, Influenza, Marketing, Conference call, Head, Hook effect, National Institute of Allergy and Infectious Diseases, COVID-19, Hepatitis, PEG, CHB, MBA, Infection, Bill & Melinda Gates Foundation, Bangladesh Technical Education Board, JJI, Congress, Conditional sentence, Patient, Vir, SAN, HPV, Bill, European Association of Urology, AI, NIAID, Johnson & Johnson, Viral hepatitis, Vaccine, CHD, HCMV, Conference, Pharmaceutical industry, Cryptocurrency, Dietary supplement, Management

ET, Aug. 3, 2023 –

Key Points: 
  • ET, Aug. 3, 2023 –
    SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.
  • Vir expects the Phase 1 trial for VIR-1388, a novel T cell vaccine for the prevention of HIV, to begin dosing in Q3 2023.
  • In June, Sasha Damouni Ellis joined Vir as Executive Vice President and Chief Corporate Affairs Officer.
  • Revenues: Total revenues for the quarter ended June 30, 2023, were $3.8 million compared to $(40.6) million for the same period in 2022.

Guerbet: Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer

Retrieved on: 
Monday, July 17, 2023
Medical imaging, Database, Male, Secretary of State for Universities, Research, Development and Innovation, Senior, Marketing, European Association of Urology, Agent handling, Cancer, Magnetic resonance imaging, Intelligence, Innovation, Prostate, Radiological Society of North America, Radiology, Development, Death, MRI, Patient, Urology, Algorithm, Annual general meeting, Neoplasm, Deep learning, GBT, Artificial intelligence, Diagnosis, Digital, WHO, RSNA, Disease, MIDL, Biopsy, Prostate cancer, Pharmaceutical industry, Guerbet, Research

The second male cancer according to the WHO, prostate cancer, with 1.4 million new cases each year worldwide, accounts for 6.8% of male cancer-related deaths (350,000 deaths per year).

Key Points: 
  • The second male cancer according to the WHO, prostate cancer, with 1.4 million new cases each year worldwide, accounts for 6.8% of male cancer-related deaths (350,000 deaths per year).
  • Magnetic resonance imaging (MRI) plays an increasingly important role in the early diagnosis of prostate cancer.
  • By training artificial intelligence on these data, it becomes possible to create a model capable of detecting the early signs of prostate cancer.
  • The PI-CAI Grand Challenge, launched in November 2022 on the detection of prostate cancer, aims to encourage technological advances in early diagnosis and accurate detection of prostate cancer and to evaluate the performance of participants' artificial intelligence algorithms.